Active Biotech AB - Company Profile
Powered by 
All the sales intelligence you need on Active Biotech AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Active Biotech AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Active Biotech AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Active Biotech AB (Active Biotech) is a biotechnology company. It focuses on the development of therapeutics in the field of cancer, inflammatory eye disorders and neurodegenerative diseases. The company’s pipeline products include naptumomab for the treatment of solid tumors and lung cancer, tasquinimod for multiple myeloma, and laquinimod for the Uveitis. The portfolio comprises antibody-based immunotherapy and small, orally active immunomodulatory molecules. It has partnerships with NeoTX Therapeutics Ltd and with the Perelman School of Medicine, University of Pennsylvania. The company’s products have patents and patent applications in markets of the US, Japan, and Europe. Active Biotech is headquartered in Lund, Sweden.
Headquarters
Sweden
Address
Scheelevagen 22, Lund, 22363
Website
www.activebiotech.com
Telephone
46 46 192000
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACTI (STO)
EPS
XYZ
Net Income (2025)
XYZ
5.3%
(2025 vs 2024)
Market Cap*
$14.5M
Net Profit Margin (0 vs)
XYZ
0.0%
(2025 vs 2024)
* As of and is in US$
Active Biotech AB premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Naptumomab Estafenatox (Naptumomab)- Solid Tumors, Lung Cancer |
| Laquinimod- Uveitis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In November, the company received notice of allowance from the US Patent Office for its patent application related to laquinimod in eye disorders. |
| 2024 | Regulatory Approval | In October, the company was granted approval for its patent application covering a proprietary developed eye drop formulation of laquinimod from the European Patent Office. |
| 2024 | Contracts/Agreements | In May, the company signed an agreement with the Wistar Institute of Anatomy and Biology, Philadelphia, the US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination therapy for multiple myeloma, for further development and commercialization. |
Competitor Comparison
| Key Parameters | Active Biotech AB | Hansa Biopharma AB | Oncopeptides AB | Alligator Bioscience AB | BioInvent International AB |
|---|---|---|---|---|---|
| Headquarters | Sweden | Sweden | Sweden | Sweden | Sweden |
| City | Lund | Lund | Stockholm | Lund | Lund |
| No. of Employees | 5 | 133 | 75 | 13 | 124 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Shalmi | Chairman | Executive Board | 2019 | 61 |
| Helen Tuvesson | Chief Executive Officer; President | Senior Management | 2017 | 64 |
| Hans Kolam | Chief Financial Officer | Senior Management | 2000 | 75 |
| Erik Vahtola | Chief Medical Officer | Senior Management | 2022 | 50 |
| Peter Thelin | Director | Non Executive Board | 2011 | 70 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer